Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angeles, CA -- (SBWIRE) -- 02/05/2014 -- Hotpennystocknews.com issues special report on - Provectus Biopharmaceuticals Inc (PVCT),IntelGenx (OTCMKTS:IGXT),RightSmile, Inc. (RIGH),Elite Pharmaceuticals Inc (OTCBB:ELTP)
Provectus Biopharmaceuticals Inc (PVCT) recently disclosed that an article describing a study to determine the potential of rose bengal disodium to cause drug-drug interactions has been published by Xenobiotica, a peer-reviewed scientific journal that publishes comprehensive research papers on pharmacokinetics (the study of distribution, metabolism, disposition and excretion of drugs).
Provectus Biopharmaceuticals Inc(PVCT) settled +49.61% higher at $1.90 on below-normal volume of 3.13 million shares during the last trading day. The stock has its 12-month high at $6.03 and 52-week low price was $0.57. It traded in a range of $1.36 to $1.95 during the last trading day.
How Should Investors React To PVCT Now? Find Out Here.
IntelGenx (OTCMKTS:IGXT), through its cutting edge formulation platforms, has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products.
IntelGenx has three proprietary delivery platforms, including an immediate release oral film, VersaFilm, a mucoadhesive tablet, AdVersa and multilayer controlled release tablet, VersaTab. IntelGenx has an aggressive product development initiative that primarily focuses on addressing unmet market needs. Their rapidly growing product pipeline consists of products at various stages of development from inception to commercialization.
According to Market Line, the global pharmaceuticals market grew by 3.5% in 2011 to reach a total value of $782.1 Billion. By the year 2016, the global pharmaceuticals market is expected to have a total value of $971.1 Billion, which represents an increase of 24.2% over the value in 2011.
Should A Trader Buy Or Sell IGXT Now : CHECK HERE.
RightSmile, Inc. (RIGH) increased 8.33% and closed at $0.0013 in the last trading session with the overall traded volume of 248.98 million shares, more versus the average volume of 225.92 million shares. Its 52 weeks high price was $0.0017 and suffered lowest price of $0.0011 in the same period. It has market cap of $5.16 million while its total outstanding shares are 3.97 billion.
RIGH works as a media marketing company in the United States and worldwide. It provides commercials, HD music videos, stills, and other services. The company also distributes cosmetic teeth whitening systems and supplies to retail outlets known as SmileShoppes. It presents cosmetic teeth whitening systems to the health and beauty retailers under the RightSmile name. RightSmile, Inc. is based in Fort Lauderdale, Florida.
Should Investors Buy RIGH Now? Free Sign Up Here For RIGH Analyst Report.
Elite Pharmaceuticals Inc (OTCBB:ELTP) is a specialty pharmaceutical company mainly engaged in the development and manufacture of oral, controlled-release products, using proprietary technology.
ELTP traded down on a volume of 4.10M, lower than its standard daily volume. Shares have dropped -5.01% to $0.285. Over the last twelve months, the stock has gain 25.14% and faced a worst price of 0.06.
Is Investor Showing Any Interest On ELTP? Find Out Here.
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)